Yagoda A, Watson R C, Whitmore W F, Grabstald H, Middleman M P, Krakoff I H
Cancer. 1977 Jan;39(1):279-85. doi: 10.1002/1097-0142(197701)39:1<279::aid-cncr2820390143>3.0.co;2-k.
Forty-two patients with measureable, advanced, genito-urinary cancer received Adriamycin. Significant clinical responses (CR/PR) occurred in only five (14%) of 35 adequately treated patients. Four additional patients achieved a minimal response anf four others showed stabilization of their disease for 4 to 9 months. Review of the literature suggests an overall response rate of 20%. Patients with a urinary diversion lived significantly longer (P 0.006) than patients who did not have this procedure (42.5 months vs 21.5 months). The need to define various patient characteristics in future chemotherapeutic trials in bladder cancer is discussed.
42例患有可测量的晚期泌尿生殖系统癌症的患者接受了阿霉素治疗。在35例得到充分治疗的患者中，仅有5例（14%）出现了显著的临床反应（完全缓解/部分缓解）。另外4例患者有微小反应，还有4例患者病情稳定了4至9个月。文献回顾显示总体缓解率为20%。行尿液改道的患者比未行此手术的患者存活时间显著更长（P = 0.006）（42.5个月对21.5个月）。文中讨论了在未来膀胱癌化疗试验中明确各种患者特征的必要性。
